Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2013 3
2014 4
2015 1
2016 1
2017 1
2018 1
2019 1
2020 1
2021 2
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.
Agnelli L, Villa A, Butt F, Duca M, Guidi A, Carapezza M, Addante M, Lenoci G, O'Regan P, Russo L, Cresta S, Castano A, Ebrahem E, Alfieri S, Patil A, Carter L, Dive C, De Braud FG, Damian S. Agnelli L, et al. Among authors: duca m. Tumori. 2024 Apr 27:3008916241248007. doi: 10.1177/03008916241248007. Online ahead of print. Tumori. 2024. PMID: 38676437 Free article.
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
Rivoltini L, Camisaschi C, Fucà G, Paolini B, Vergani B, Beretta V, Damian S, Duca M, Cresta S, Magni M, Leone BE, Castelli C, de Braud F, De Santis F, Di Nicola M. Rivoltini L, et al. Among authors: duca m. Sci Rep. 2024 Feb 9;14(1):3379. doi: 10.1038/s41598-024-54041-9. Sci Rep. 2024. PMID: 38336861 Free PMC article. Clinical Trial.
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Vingiani A, et al. Among authors: duca m. JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067. JCO Precis Oncol. 2023. PMID: 37487147 Free PMC article.
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples.
Capone I, Bozzi F, Dagrada GP, Verderio P, Conca E, Busico A, Testi MA, Monti V, Duca M, Proto C, Damian S, Piccolo A, Perrone F, Tamborini E, Devecchi A, Collini P, Lorenzini D, Vingiani A, Agnelli L, Pruneri G. Capone I, et al. Among authors: duca m. Explor Target Antitumor Ther. 2022;3(5):582-597. doi: 10.37349/etat.2022.00102. Epub 2022 Oct 27. Explor Target Antitumor Ther. 2022. PMID: 36338518 Free PMC article.
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
Fucà G, Lecchi M, Ciniselli CM, Ottini A, Spagnoletti A, Mazzeo L, Morelli D, Frati P, Stroscia M, Ebrahem E, Sottotetti E, Galli G, D'Elia MG, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S, Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, de Braud F, Verderio P, Damian S. Fucà G, et al. Among authors: duca m. Ther Adv Med Oncol. 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923922 Free PMC article.
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S. Azzollini J, et al. Among authors: duca m. Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515. eCollection 2022. Front Oncol. 2022. PMID: 35463374 Free PMC article.
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D'Alessio JA, Abrams T, Sheng Q, Tan EY, Rosa MS, Gonzalez-Maffe J, Sand-Dejmek J, Fabre C, Martin M. Duca M, et al. Mol Cancer Ther. 2022 Apr 1;21(4):625-634. doi: 10.1158/1535-7163.MCT-21-0652. Mol Cancer Ther. 2022. PMID: 35131875 Clinical Trial.
28 results